Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Clinical trial NCT01121588 · TERMINATED
Trial details
- NCT number
- NCT01121588
- Sponsor
- Pfizer
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2011-03-22
- Primary completion
- 2023-09-07
- Enrollment
- 44
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.